Bilaketaren emaitzak - Matthias Pinter

Findu emaitzak
  1. 1
    Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

    Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy nork Matthias Pinter, Rakesh K. Jain

    Argitaratua 2017
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Review article: systemic treatment of hepatocellular carcinoma

    Review article: systemic treatment of hepatocellular carcinoma nork Matthias Pinter, Markus Peck‐Radosavljevic

    Argitaratua 2018
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups nork Matthias Pinter, Bernhard Scheiner, Markus Peck‐Radosavljevic

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Renin–Angiotensin System Inhibitors to Mitigate Cancer Treatment–Related Adverse Events

    Renin–Angiotensin System Inhibitors to Mitigate Cancer Treatment–Related Adverse Events nork Matthias Pinter, Wilhelmus J. Kwanten, Rakesh K. Jain

    Argitaratua 2018
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  5. 5
    The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma

    The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma nork Matthias Pinter, Rakesh K. Jain, Dan G. Duda

    Argitaratua 2020
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Cancer and liver cirrhosis: implications on prognosis and management

    Cancer and liver cirrhosis: implications on prognosis and management nork Matthias Pinter, Michael Trauner, Markus Peck‐Radosavljevic, Wolfgang Sieghart

    Argitaratua 2016
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy

    NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy nork Matthias Pinter, David J. Pinato, Pierluigi Ramadori, Mathias Heikenwälder

    Argitaratua 2022
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  8. 8
    The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study

    The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study nork Matthias Pinter, Wolfgang Sieghart, Thomas Reiberger, Nataliya Rohr‐Udilova, Arnulf Ferlitsch, Markus Peck‐Radosavljevic

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis

    Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis nork Matthias Pinter, Wolfgang Sieghart, Ivo Graziadei, Wolfgang Vogel, A Maieron, Robert Königsberg, Adalbert Weißmann, Gabriela Kornek, Christina Plank, Markus Peck‐Radosavljevic

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers

    Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers nork Vera Himmelsbach, Matthias Pinter, Bernhard Scheiner, Marino Venerito, Friedrich Sinner, Carolin Zimpel, Jens U. Marquardt, Jörg Trojan, Oliver Waidmann, Fabian Finkelmeier

    Argitaratua 2022
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol

    Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol nork Thomas Reiberger, Gregor Ulbrich, Arnulf Ferlitsch, B.A. Payer, Philipp Schwabl, Matthias Pinter, Birgit Heinisch, Michael Trauner, Ludwig Kramer, Markus Peck‐Radosavljevic

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality

    Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality nork Dalila Costa, Benedikt Simbrunner, Mathias Jachs, Lukas Hartl, David Bauer, Rafael Paternostro, Philipp Schwabl, Bernhard Scheiner, Albert Friedrich Stättermayer, Matthias Pinter, Michael Trauner, Mattias Mandorfer, Thomas Reiberger

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient

    Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient nork Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, Georg Semmler, Lorenz Balcar, Benedikt Hofer, Michael Schwarz, David Bauer, Albert Friedrich Stättermayer, Matthias Pinter, Michael Trauner, Thomas Reiberger, Mattias Mandorfer

    Argitaratua 2024
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade

    A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade nork Ivy X. Chen, Kathleen Newcomer, Kristen E. Pauken, Vikram R. Juneja, Kamila Naxerova, M. Wu, Matthias Pinter, Debattama R. Sen, Meromit Singer, Arlene H. Sharpe, Rakesh K. Jain

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study

    Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to... nork Katharina Pomej, Adrian Frick, Bernhard Scheiner, Lorenz Balcar, Larissa Pajancic, Anton Klotz, Alexander Kreuter, Katharina Lampichler, Katharina Regnat, Kerstin Zinober, Michael Trauner, Dietmar Tamandl, Christoph Gasché, Matthias Pinter

    Argitaratua 2025
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma

    Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma nork Bernhard Scheiner, Martha M. Kirstein, Sabine Popp, Florian Hucke, Simona Bota, Nataliya Rohr‐Udilova, Thomas Reiberger, Christian Müller, Michael Trauner, Markus Peck‐Radosavljevic, Arndt Vogel, Wolfgang Sieghart, Matthias Pinter

    Argitaratua 2018
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death

    Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death nork Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, David Bauer, Rafael Paternostro, Bernhard Scheiner, Philipp Schwabl, Albert Friedrich Stättermayer, Matthias Pinter, Ernst Eigenbauer, Peter Quehenberger, Michael Trauner, Thomas Reiberger, Mattias Mandorfer

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension

    The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension nork Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, David Bauer, Rafael Paternostro, Bernhard Scheiner, Lorenz Balcar, Georg Semmler, Albert Friedrich Stättermayer, Matthias Pinter, Peter Quehenberger, Michael Trauner, Thomas Reiberger, Mattias Mandorfer

    Argitaratua 2022
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma

    Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma nork Matthias Pinter, Arndt Weinmann, Marcus‐Alexander Wörns, Florian Hucke, Simona Bota, Jens U. Marquardt, Dan G. Duda, Rakesh K. Jain, Peter R. Galle, Michael Trauner, Markus Peck‐Radosavljevic, Wolfgang Sieghart

    Argitaratua 2017
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Safety of direct oral anticoagulants in patients with advanced liver disease

    Safety of direct oral anticoagulants in patients with advanced liver disease nork Georg Semmler, Katharina Pomej, David Bauer, Lorenz Balcar, Benedikt Simbrunner, Teresa Binter, Lukas Hartl, Jeannette Becker, Matthias Pinter, Peter Quehenberger, Michael Trauner, Mattias Mandorfer, Ton Lisman, Thomas Reiberger, Bernhard Scheiner

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: